Background-Experimental studies suggest that deferoxamine (DFO) limits the generation of reactive oxygen species by chelating redox-active iron and thereby may reduce ischemia-reperfusion injury and myocardial infarct (MI) size. We investigated whether DFO administered before reperfusion by primary percutaneous coronary intervention (PPCI) would ameliorate oxidative stress and MI size. Methods and Results-We randomly assigned 60 patients with ST-elevation-MI to receive an intravenous bolus of DFO (500 mg) immediately before PPCI followed by a 12-hour infusion (50 mg/kg of body weight) (nϭ28) or normal saline bolus and infusion (placebo group, nϭ32). MI size was measured by contrast-enhanced cardiac MRI (CMRI; day 3Ϯ1), creatine kinase and troponin I area-under-the-curve, and severity of wall motion abnormality on echocardiography. Clinical follow-up including repeat CMRI and echocardiography were performed at 3 months (100Ϯ17 days). Oxidative stress was assessed by plasma F 2 -isoprostane levels. DFO and placebo groups were well balanced with respect to baseline characteristics, symptom-and door-to-balloon times, pre-PPCI coronary patency, and infarct-related artery location. Serum iron levels were decreased with DFO treatment after PPCI compared with placebo (3.0Ϯ2.5 versus 12.6Ϯ5.5 mol/L, PϽ0.0001), which persisted until the end of the infusion. In DFO-treated patients, there was a significant reduction in plasma F 2 -isoprostane levels immediately after PPCI (2878Ϯ1461 versus 2213Ϯ579 pmol/L, Pϭ0.04). 
xperimental studies suggest that reactive oxygen species (ROS) are the major biological mediator of ischemiareperfusion injury. 1 These can form during acute myocardial ischemia under low oxygen tension, 2 but particularly during the first few minutes of reperfusion. 3, 4 Redox-active iron released from macrophages 5 and intracellular myocyte stores 6 is capable of catalyzing ROS production via Fenton chemistry to generate potent oxidants (including the highly reactive hydroxyl radical, OH•) that participate in lipid peroxidation and cellular injury. 7, 8 Deferoxamine (or desferrioxamine; DFO) is an extracellular iron chelator 9 with an extremely high affinity constant (Kdϭ10 31 ) for Fe 3ϩ , which underlies its principal inhibitory effect on OH• generation, 10 forming a stable complex with Fe 3ϩ and decreasing its availability for ROS production. 11 DFO has also been shown to reduce ROS formation by directly scavenging the OH• radical 8, 12 and inhibiting endothelial cell activation in response to tumor necrosis factor-␣ and collagen-induced whole-blood platelet aggregation. 13 We have previously demonstrated that iron chelation with DFO in patients with coronary artery disease improved forearm endothelial-mediated, nitric oxide-dependent blood flow, 14 an effect that might translate into improved coronary blood flow. 15 Experimental studies with DFO at the time of postischemic reflow resulted in greater recovery of myocardial function and energy metabolism 10 and decreased infarct size in canines. 16 In a randomized, placebo-controlled study of 45 patients undergoing cardiopulmonary bypass, DFO infused intravenously immediately after anesthesia reduced ROS production and improved left ventricular ejection fraction postoperatively and after 12 months. 17 No studies have examined the effectiveness of DFO in the setting of STEMI. Therefore, the primary aim of this randomized, double-blind, placebo-controlled study was to investigate whether iron chelation with DFO in patients with ST-segment elevationmyocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PPCI) ameliorates oxidative stress and reduces infarct size determined by cardiac MRI (CMRI) and creatine kinase and troponin I area-under-thecurve measurements.
WHAT IS KNOWN
• Ischemia-reperfusion injury is a well-recognized contributor to myocardial infarct size in experimental coronary artery occlusion and in clinical STelevation-myocardial infarction (STEMI).
• The pathophysiology of ischemia-reperfusion injury is complex and multifactorial and includes the production of reactive oxygen species (ROS) on reperfusion and the continued postinfarct inflammatory response.
• Redox-active iron released from macrophages and myocyte intracellular stores is capable of catalyzing ROS production via Fenton chemistry to generate potent oxidants that participate in lipid peroxidation and cellular injury.
WHAT THE STUDY ADDS
• This study tested the hypothesis that decreasing the production of ROS by iron chelation with deferoxamine might reduce ischemia-reperfusion injury and decrease myocardial infarct size.
• In a randomized, placebo-controlled trial, iron chelation with deferoxamine after the onset of ischemia and continued periprocedurally in primary percutaneous coronary intervention for STEMI reduced serum iron concentrations and ameliorated oxidative stress but did not limit infarct size compared with placebo.
• Numerous classes of pharmacological agents, including deferoxamine, although showing promise in experimental models of myocardial infarction, have not translated positively in clinical trials.
Methods

Study Participants
Consecutive patients Ͼ18 years of age admitted with first presentation STEMI with chest pain Ն30 minutes in duration (to reduce recruitment of aborted infarcts), symptom onset Ͻ6 hours, and ECG changes of new ischemia (ST elevation at the J point Ն0.1 mV in 2 contiguous leads) were invited to participate. All patients having 1 or more of the following criteria were excluded: an intracardiac device not compatible with CMRI (eg, pacemaker); suspected or known previous MI in the same coronary artery territory as the current STEMI; rescue angioplasty; cardiogenic shock (systolic blood pressure Ͻ90 mm Hg); current iron supplementation or known iron deficient state; renal failure (estimated glomerular filtration rate Յ30 mL/min); known hypersensitivity to DFO; or severe claustrophobia.
Trial Design
This was a prospective, single-center, randomized, double-blind, placebo-controlled study. DFO (Novartis Pharmaceuticals, North Ryde, Australia) was purchased using a National Health Figure 1 . An intravenous bolus dose of 500 mg of DFO reconstituted in 10 mL of water for injection (or normal saline in the placebo group) was given over 5 to 10 minutes before reperfusion by PPCI, followed by an infusion of 50 mg/kg of DFO (or placebo) over a 12-hour period (equivalent to 4.1 mg/kg per hour in an 80-kg patient). The DFO bolus dosage was chosen on the basis of work by Nitenberg et al, 15 who infused 500 mg of DFO over a 10-minute period in diabetic patients to restore the coronary artery endothelium-dependent vasodilator response to cold pressor testing and papaverine. The aim of the bolus was to achieve sufficient DFO plasma concentration and consequent iron chelation before reperfusion, as the extent of ischemia-reperfusion injury appears to be greatest immediately after reperfusion. 3, 4 The infusion dose was the same as that used by Paraskevaidis et al 17 prepared by dissolving the prescribed amount of DFO powder, based on weight with water for injection to achieve a solution with a concentration of 10% (as per manufacturer recommendation). The solution was then further diluted in 0.9% normal saline to achieve a final volume of 100 mL to standardize the amount of fluid given in both study arms. Neither the patient, the treating interventional cardiologist, the subsequent coronary care cardiologists, nor those measuring MI size had knowledge of treatment assignment. Random assignment was performed by the Alfred Hospital Pharmacy using a computer-generated randomization sequence. Study envelopes were numbered, sealed, and stratified according to infarct-related artery distribution (anterior [left anterior descending artery, LAD] STEMI versus nonanterior STEMI).
Routine Patient Treatment
Coronary angiography was performed according to standard techniques. Revascularization was performed by stenting preceded by balloon predilatation. Adjunctive aspirin, clopidogrel, and intravenous unfractionated heparin were given. Periprocedural use of glycoprotein IIb/IIIa receptor antagonists and/or thromboaspiration was at the discretion of the treating interventional cardiologist. All patients were invited to return in 3 months for clinical review and additional scanning with CMRI and echocardiography.
ECG Analysis
A blinded observer performed all analysis of ST-segment resolution from a preprocedural 12-lead ECG compared with the first postprocedural ECG, usually performed within 30 to 90 minutes after PPCI on the coronary care ward according to established guidelines. 18 
Biochemical Analysis
Serum iron parameters (iron, ferritin, soluble transferrin receptor) were measured before PPCI, after PPCI, at the end of DFO infusion, and at 3 months. Routine laboratory analyses including full blood examination, high-sensitivity C-reactive protein, and renal and liver function tests were measured by the Alfred Hospital Pathology Service on commercially available automated platforms. Creatine kinase and troponin I measurements were obtained before PCI and then at 6-hourly intervals over 48 hours to determine the area-underthe-curve by computerized planimetry (Image J1.32j, http://rsb.info. nih.gov/ij/). 19 To minimize ex vivo oxidation, blood samples for F 2 -isoprostanes were collected in ice-cold EDTA tubes (18 mg EDTA for 10 mL of whole blood). Reduced glutathione (1 mg/mL) and butylated hydroxytoluene (200 mg/mL) were added as antioxidants before centrifugation at 3000 rpm for 15 minutes at 4°C within 30 minutes of collection. Plasma was stored at Ϫ80°C until analysis by gas chromatography-mass spectrometry using electron capture negative chemical ionization as previously described. 20 
Angiographic Analysis
Angiographic lesion characteristics were classified according to the modified American Heart Association/American College of Cardiology classification from 2 orthogonal planes. Preprocedural and postprocedural assessments of epicardial TIMI (Thrombolysis In Myocardial Infarction) flow grade was performed by the treating interventional cardiologist blinded to patient treatment assignment. Procedural factors including symptom-and door-to-balloon inflation, glycoprotein IIb/IIIa inhibitors, thromboaspiration, and type of implanted stent were recorded.
CMRI Protocol and Analysis
All CMRI were performed on a clinical 1.5-T CMRI scanner (Signa HDx 1.5-T, GE Healthcare, Waukesha, WI). Left ventricular (LV) function was assessed by a standard steady-state free precession technique (repetition time [TR], 3.8 ms; echo time [TE], 1.6 ms; 30 phases; and slice thickness of 8 mm). LV ejection fraction was calculated by volumetric analysis from a contiguous short-axis stack (8-mm slice thickness), using the summation of disc method by at least 2 blinded cardiologists (A.J.T., A.H.E., and L.L.). For area-atrisk determination, LV short-axis slices covering the whole ventricle using a T2-weighted triple-inversion recovery breath-hold fast spinecho pulse sequence (short tau inversion recovery; STIR) (TR 2 R-to-R intervals, TE, 80 ms; inversion time [TI] , 150 ms; slice thickness, 8 mm; field of view, 40 m; matrix, 224ϫ224) were obtained using a body coil. Area-at-risk was quantified by manual delineation of myocardium with bright signal intensity 2 SD above the mean signal obtained in the remote, noninfarcted myocardium and multiplying the slice thickness and the myocardial density of 1.05 g/mL, expressed as a percentage of LV mass. Late enhancement images covering the whole ventricle were acquired approximately 15 minutes after intravenous administration of a bolus of gadoliniumdiethylene triamine penta-acetic acid (DTPA) (0.2mmol/kg, Magnevist, Schering, Germany) to identify regional necrosis/fibrosis for infarct size quantification using an inversion recovery gradient echo technique (TR, 7.1 ms; TE, 3.1 ms; TI individually determined to null the normal myocardial signal, range, 180 -250 ms; slice thickness, 8 mm; matrix, 256ϫ192; number of acquisitionsϭ2). The area of hyperenhanced myocardium (bounded by endocardial and epicardial contours) on each short-axis slice was manually traced then multiplied by the slice thickness and the myocardial density of 1.05 g/mL to obtain the infarct mass and expressed as a percentage of LV mass (infarct size). 19 Myocardial salvage index was calculated as the area-at-risk minus percentage infarct size divided by area-at-risk. 21 All analyses were performed offline on dedicated workstations running AW SDC 4.4 and IDL version 6.3 with ReportCARD version 3.6 by fully blinded observers with excellent reproducibility (rϭ0.98) for infarct size assessment.
Echocardiographic Assessment
Blinded echocardiographic assessment of LV volume and function were performed on day 3 to 5 and at 3 months, using the Simpson biplane method (Vivid 7 systems; GE Vingmed, Horten, Norway). Regional wall motion abnormalities (wall motion score index, WMSI) were scored according to the American Society of Echocardiography 16-segment model.
Statistical Analysis
Categorical data are presented as numbers and percentages. Continuous data are presented as meanϮSD unless otherwise stated. Continuous variables were compared with either paired or unpaired Student t test; categorical variables were compared between groups with Pearson 2 test or a Fisher exact test where appropriate. Variables were checked for normality, and, where failed, logarithmic transformation of the data was performed before analysis; otherwise, nonparametric testing was performed. MeanϮSD values are presented as raw data to facilitate interpretation. Repeated-measures ANOVA with post hoc testing (Bonferroni) for multiple comparisons was used to assess for treatment effects. Sample size estimation was based on creatine kinase and infarct size dataset from previously published studies. 19, 22 Based on a hypothesized 30% reduction in the area-under-the-curve for creatine kinase in the DFO group, we required 31 patients per group to achieve a statistical power of 80% and a probability of a type I error of 0.05 using a 2-sided test. 19 The primary end point was MI size measured by both creatine kinase/ troponin I area-under-the-curve and CMRI. CMRI-determined infarct size was analyzed according to treatment, location of infarct (anterior/nonanterior), pre-PCI TIMI 0 flow grade, and ischemia time (symptom-to-balloon). All reported probability values are 2-sided. Probability values Ͻ0.05 were considered statistically significant. All data analyses were performed with SPSS version 16 (SPSS Inc, Chicago, IL).
Results
Baseline and Procedural Characteristics
A total of 245 consecutive patients presented to the Alfred Hospital with ST-segment elevation and symptoms suggestive of STEMI from August 2008 to December 2010. Seventy-six patients were enrolled into the study, and 60 patients were included in the final analysis. The 16 patients initially deemed eligible but subsequently omitted from the analysis were excluded for the following reasons: 12 had no infarct-related artery and 4 patients underwent emergency coronary artery bypass grafting. One hundred sixty-nine patients were excluded for the following reasons: 45 received fibrinolysis (at other institutions and transferred for ongoing care); 32 presented with symptoms Ͼ6 hours duration; 25 were out-of-hospital cardiac arrests; 19 were not assessed because the primary investigator (W.C.) was not available; 17 patients had either stent thrombosis or previous STEMI in the same territory; 16 were deemed hemodynamically unstable or in cardiogenic shock; and 15 declined participation (see Figure 1) .
The DFO and placebo groups were well balanced with respect to baseline characteristics (Table 1) Table 2 ). The number of coronary stents implanted and the mean stent length was greater in the DFO group. However, all other procedural variables including pre-and post-PCI TIMI flow grades, use of glycoprotein IIb/IIIa receptor antagonists, use of thromboaspiration, and clopidogrel preloading were similar between the 2 groups.
Measures of Serum Iron, Oxidative Stress, and Inflammation
Post-PPCI serum iron was significantly reduced in the DFO group compared with placebo (3.0Ϯ2.5 versus 12.6Ϯ5.5 mol/L, PϽ0.0001; Figure 2 ). Serum iron remained significantly decreased in the DFO group for the duration of the 12-hour infusion (1.5Ϯ1. Pre-PPCI plasma F 2 -isoprostane levels were similar between DFO and placebo groups (2878Ϯ1461 versus 2,362Ϯ921 pmol/L, Pϭ0.10). However, after PPCI there was a significant reduction in F 2 -isoprostane levels in the DFO but not placebo group (⌬ 616Ϯ1397 versus 351Ϯ1031 pmol/L; Pϭ0.04 for pre-PPCI versus post-PPCI intragroup comparison [ Figure 3] ). However, analysis of the change in plasma F 2 -isoprostane levels before and after PCI was not statistically significant between DFO and placebo groups (Pϭ0.43).
Plasma C-reactive protein levels were similar between DFO and placebo groups on admission 
Early MI Size and Salvage Assessment
More than 70% of patients in both groups (DFOϭ21 and placeboϭ23) underwent CMRI at a mean of 3Ϯ1 days after STEMI. MI size (17.4Ϯ10.8% versus 18.6Ϯ10.2%, Pϭ0.73) and myocardial salvage index (33.8Ϯ23.1% versus 30.8Ϯ24.5%, Pϭ0.70) were not different between the DFO or placebo groups (Figure 4) . Similar results were obtained when only patients with pre-PPCI TIMI 0 flow were included (21.2Ϯ10.0% versus 18.0Ϯ9.8%, Pϭ0.37) ( Figure 4C ). In further prespecified analyses of MI size according to ischemia (symptom-to-balloon) time and infarct-related artery location, the MI size was also similar in both groups ( Figure 5 ).
Creatine kinase (15 086Ϯ12 749 versus 14 816Ϯ10 270 arbitrary units for area-under-the-curve) and troponin I (16 326Ϯ22 181 versus 14 535Ϯ15 950 arbitrary units) release after PPCI was similar between DFO and placebo groups (Pϭ0.93 and 0.72, respectively; Figure 6 ). Peak creatine kinase and troponin I between DFO and placebo groups were 2304Ϯ1869 versus 2635Ϯ2234 IU/L (Pϭ0.54) and 86.13Ϯ105.73 versus 74.28Ϯ71.12 g/L (Pϭ0.61), respectively. The mean ST-segment resolution between DFO and placebo groups was 67% versus 64%, respectively (Pϭ0.67). Analysis of WMSI by echocardiography also showed no difference between the 2 groups with respect to the degree of wall motion abnormality (DFO, 1.46Ϯ0.34 versus placebo, 1.60Ϯ0.28; Pϭ0.10).
MI Size and Salvage Assessment at 3 Months
At 3 months of follow-up, 16 (57%) DFO and 20 (62%) placebo patients returned for their CMRI (mean, 100Ϯ17 days). Neither infarct size nor MSI were different between DFO and placebo groups (Figure 7) . Echocardiographic WMSI assessment also showed no significant difference between the 2 groups at 3 months (1.42Ϯ0.32 versus 1.41Ϯ0.32, Pϭ0.85). In those who did not undergo CMRI assessment at 3 months but who completed echocardiographic assessment, there was also no difference in LV ejection fraction between DFO and placebo groups (50.3Ϯ8.1% versus 48.9Ϯ9.2%, Pϭ0.76) nor WMSI (1.52Ϯ0.31 versus 1.39Ϯ0.39, Pϭ0.51).
Clinical Follow-Up and Study Safety
We did not observe any serious adverse events related to DFO bolus administration or throughout the 12-hour infusion after PPCI necessitating cessation of the study medication. At 3 months, 1 patient in the DFO group died compared with 2 patients in the placebo group. Four patients in the DFO group were readmitted after discharge (2 with heart failure, 1 with nonischemic chest pain, and 1 with melena), whereas 2 patients in the placebo arm were readmitted with atypical chest pains not due to recurrent ischemia. The 3-month cumulative incidence of heart failure was similar between DFO and placebo groups: 5 (18%) versus 7 (23%) (Pϭ0.70).
LV ejection fraction by CMRI in both DFO and placebo groups improved from baseline to 3 months (DFO, 49.1Ϯ10.1% to 56.0Ϯ11.6%, Pϭ0.01; and placebo, 48.9Ϯ5.4% to 52.4Ϯ7.2%, Pϭ0.01). Serum iron levels (18.6Ϯ4.6 versus 17.2Ϯ5.2 mol/L, Pϭ0.38) and C-reactive protein levels (1.6Ϯ1.2 versus 3.3Ϯ6.7 mg/L, Pϭ0.32) were comparable between the 2 groups at 3 months.
Discussion
In this randomized, double-blind, placebo-controlled study using iron chelation with deferoxamine to target ischemiareperfusion injury in patients with STEMI treated by PPCI, there was no significant difference observed in the primary end point of MI size whether determined by CMRI, cardiac DFO indicates deferoxamine; ASA, aspirin; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; LAD, left anterior descending artery; LCx, left circumflex; RCA, right coronary artery; TIMI, Thrombolysis in Myocardial Infarction; PCI, percutaneous coronary intervention; GP, glycoprotein; BMS, bare metal stent; and DES, drug-eluting stent. biomarker release, ST-segment resolution, or echocardiographic WMSI. However, deferoxamine effectively decreased serum iron levels and oxidative stress as measured by plasma F 2 -isoprostanes after PPCI. These data show that despite achieving a reduction in oxidative stress with active treatment that MI size was not favorably affected.
Experimental studies suggest that ROS are the major biological mediator of ischemia-reperfusion injury. 1 ROS can form during acute myocardial ischemia under low oxygen tension, 2 reaching peak levels during the first few minutes after reperfusion. 3, 4 Iron, which is the most abundant transition metal in mammalian cells, exists predominantly in the bound form (with ferritin). However, the redox-active form can readily participate in the Fenton reaction to generate ROS to induce lipid peroxidation and cellular injury. 7 Thus, redoxactive iron released from macrophages 5, 23 and intracellular myocyte ferritin stores 6, 24 are potential targets for iron chelation by DFO, which has long been known to ameliorate lipid peroxidation due to its extremely high affinity constant for Fe 3ϩ . 10, 11 Additionally, DFO may also directly scavenge the OH• radical 12 and improve endothelial function, [13] [14] [15] which might improve coronary blood flow. 15 Animal studies using DFO at the time of postischemic reflow resulted in greater recovery of myocardial function 8 and energy metabolism. 10 Importantly, iron in the effluent of treated rabbit hearts was in the form of Fe 3ϩ -DFO chelates, suggesting that DFO reached adequate levels in the myocardium. 10 Studies in canines with DFO administration before the onset of ischemia also resulted in decreased infarct size. 16 No clinical studies, to our knowledge, have tested the feasibility, safety, or effectiveness of DFO therapy in patients with STEMI treated by PPCI and other contemporary pharmacological therapies.
We administered a bolus dose of DFO with the aim of achieving sufficient plasma concentration at the time of reperfusion to maximally chelate iron and inhibit the burst of ROS production after reperfusion. 3, 4 The bolus dosage was chosen based on work by Nitenberg et al, 15 who showed that 500 mg DFO led to improved coronary artery vasodilator Figure 3 . Plasma F 2 -isoprostane levels before and after percutaneous coronary intervention (PCI). Before primary PCI (PPCI), F 2 -isoprostane levels were comparable between the treatment groups (Pϭ0.10), but there was a significant fall after PPCI in the deferoxamine (DFO) group only. responses in diabetic patients. Given the relatively short half-life of DFO (5-7 minutes 25 ) and possible ongoing ROS production during the acute inflammatory and prooxidant phase after STEMI associated with neutrophil infiltration, 26 it was critical that DFO levels be maintained to continue myocardial iron chelation. Thus, we continued DFO therapy as a 12-hour infusion after PPCI to target ongoing ironmediated ROS production and achieved consistently low levels of serum iron.
DFO treatment was well tolerated and safe, with no observed toxicity or adverse events attributable to either the bolus or infusion in the periprocedural period and up to 3 months of clinical follow-up. After the DFO bolus, serum iron levels were significantly reduced compared with the placebo group, with some patients achieving levels of Ͻ1.0 mol/L. Serum iron levels also remained significantly depressed for the duration of DFO infusion. Plasma F 2 -ispoprostane levels were chosen as the measure of oxidative stress because available evidence suggest they are the most sensitive and specific in vivo markers of lipid peroxidation in humans. 27, 28 In the DFO-treated group, plasma F 2 -isoprostane levels were reduced significantly after the DFO bolus compared with the placebo group, suggesting greater amelioration of oxidative stress by DFO. However, we did not measure F 2 -isoprostane levels at the end of the DFO infusion (owing to the complex sample preparation required out of hours), when one might have expected a further reduction in oxidative stress in the active treatment group. Notably, the degree of post-STEMI inflammation, as assessed by C-reactive protein plasma levels, was not different between the 2 groups before PCI, after PCI, at 48 hours or at 3 months.
Despite the observed reduction in oxidative stress after DFO bolus treatment, the primary end point of MI size was not reduced in the DFO group when measured by CMRI, cardiac biomarker release, or WMSI by echocardiography at 3 days and at 3 months. Indices of LV systolic function and volumes and LV mass were also not significantly different between the 2 groups at 3 days and at 3 months, though LV ejection fraction improved in both groups at 3 months. Prespecified analysis of MI size according to treatment, pre-PCI TIMI 0 flow, infarct-related artery location, and ischemia time also yielded similar MI sizes between the 2 groups, suggesting the DFO treatment had no effect on MI size in any subgroups. We also assessed the effectiveness of DFO in myocardial salvage by measuring the myocardial salvage index, which is increasingly being used to underscore the success of various reperfusion strategies without the need to employ large numbers of patients 21, 29 and has been suggested as a better surrogate end point than infarct size per se. 30 However, myocardial salvage index measured at 3 days and at 3 months was also not different between the 2 groups.
There are several possibilities that may account for the lack of benefit with DFO treatment in our study. First, as there are no prior clinical studies of DFO therapy in the setting of STEMI, iron chelation may simply not be effective in this context in humans. Alternatively, iron-catalyzed ROS generation may not be a major contributor to ischemia-reperfusion injury in STEMI in humans. Previous cardiovascular studies with DFO in humans have been exclusively in setting of cardiopulmonary bypass, a potent stimulant of oxidative stress. 17 However, cardiopulmonary bypass is a vastly different clinical scenario to STEMI. Second, the timing of therapy in relation to the onset of ischemia appears critical. In contrast to the study by Paraskevaidis et al 17 and in animal studies, 16 DFO administration in our study was after the onset of ischemia rather than before ischemia. The previously observed improvements in postischemic LV function and MI size when treatment was administered before ischemia may not consistently translate to a beneficial effect when given after ischemia or just before reperfusion, as evidenced from studies with other agents as well. 31 Third, our patient population was different from cohorts treated in other recent positive studies. 19, 22, 29 For example, we did not have an upper age limit and included a few patients (nϭ16) with pre-PCI TIMI 1, 2, and 3 flow (which may have represented aborted infarcts). We also did not exclude patients based on the presence of collaterals or prior chest pain (which may have induced ischemic preconditioning). Thus, our study population may have been a more heterogeneous cohort than in these other recent studies and may have reduced our chances of detecting a possible benefit with DFO therapy. Fourth, as DFO is poorly cell permeable and predominantly acts as an extracellular iron chelator, this can potentially limit the success of intracellular iron chelation and the reduction of intracellular ROS generation and cytotoxicity. 32 Finally, it is possible that despite the use of a DFO bolus, DFO may not have reached the ischemic myocardium in sufficient concentration to reduce oxidative stress and limit ischemiareperfusion injury immediately on reperfusion; a scenario similar to that observed with other agents. 31 
Limitations
The principal limitation of this study is the relatively small sample size of 60 patients, which may be underpowered to detect the hypothesized 30% reduction in creatine kinase area-under-the-curve between the 2 treatment groups. However, we based our study size on trials using similar methodology and finding positive results. 19, 22 Also, post hoc power calculation using CMRI determined infarct size difference of 20Ϯ10% suggested that we would require a sample size of 45 per group to achieve a statistical power of 80% with a probability of a type I error of 0.05 to detect a 30% reduction in MI size with DFO. However, given the apparent lack of benefit observed with respect to MI size and myocardial salvage index across the treatment groups, infarct-related artery location, pre-PCI TIMI 0 flow, and ischemia time, both at 3 days and at 3 months, it is unlikely that a larger sample size would detect clinically significant differences with treatment. Another limitation is that only 60% of patients successfully completed their 3-month CMRI assessment. However, in those who did not undergo CMRI assessment at 3 months but who completed echocardiographic assessment, there was also no difference in LV ejection fraction or wall motion score index between DFO and placebo groups. We based our DFO dosing on prior clinical studies but these were performed in the non-STEMI setting. It is possible that our DFO dose may not have been optimal to achieve sufficient myocardial levels at the time of reperfusion as much higher doses of (up to 100 mg/kg) are used in patients with ␤-thalassaemia major with cardiac disease. 33 Despite these concerns, we observed a reduction in serum iron and decreased plasma markers of oxidative stress with the DFO regimen used.
Conclusion
In summary, DFO treatment commenced after the onset of ischemia but before reflow in patients with STEMI treated by PPCI failed to limit infarct size and improve myocardial salvage despite prompt amelioration of oxidative stress.
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